| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
Fiscal Year 2014: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Two studies about breast conservation therapy (BCT) were performed.First study was performed to investigate whether the presence of the receptor tyrosine kinase-GEP100-Arf6-AMAP1 pathway correlate with local recurrence (LR) after BCT. Using 19 specimens with LR, immunohistochemical staining of EGFR, HER2, GEP100 and AMAP1 was performed. Strongly positive for both GEP100 and AMAP1 group shows a shorter time to LR after the completion of radiotherapy than the others.This study shows that co-overexpression of GEP100 and AMAP1 protein correlate with rapid LR after BCT. Next, dosimetric comparison study which compare spot scanning proton therapy (SSPT) to intensity modulated radiotherapy (IMRT). Three different planning target volume (PTV) which include affected breast with or without regional lymph node. Dose to PTVs and organ at risks (OARs; ipsilateral lung, heart and contralateral lung) were calculated and compared. The SSPT reduced the dose to OARs with adequate target coverage.
|
